Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.
|
Submission of Matters to a Vote of Security Holders. |
At our Annual Meeting of stockholders held on May25, 2017, our
stockholders voted on four matters as follows:
| 1. |
The following seven nominees were elected to our Board of Directors to serve for a one-year term expiring at the 2018 annual meeting of stockholders: |
| Votes For | Votes Against | Votes Abstaining | Broker Non-Votes | |||||||||||||
|
Jeffrey Berkowitz, J.D. |
32,849,653 | 795,142 | 27,276 | 10,160,694 | ||||||||||||
|
Anthony B. Evnin, Ph.D. |
32,817,536 | 840,259 | 14,276 | 10,160,694 | ||||||||||||
|
Michael G. Kauffman, M.D., Ph.D. |
32,532,279 | 1,127,316 | 12,476 | 10,160,694 | ||||||||||||
|
Adelene Q. Perkins |
32,782,969 | 727,429 | 161,673 | 10,160,694 | ||||||||||||
|
Norman C. Selby |
32,791,412 | 799,453 | 81,206 | 10,160,694 | ||||||||||||
|
Ian F. Smith |
33,038,856 | 619,120 | 14,095 | 10,160,694 | ||||||||||||
|
Michael C. Venuti, Ph.D. |
32,790,768 | 852,008 | 29,295 | 10,160,694 | ||||||||||||
| 2. |
A non-binding, advisory proposal on the compensation of the Companys named executive officers was approved. |
|
Votes For |
VotesAgainst |
VotesAbstaining |
Broker Non-Votes |
|||
|
24,174,001 |
9,462,624 | 35,446 | 10,160,694 |
| 3. |
The shareholders recommended, in a non-binding, advisory vote, that future advisory votes on the compensation of the Companys named executive officers be held every three years. |
|
Every3Years |
Every2Years |
Every1Year |
Abstain |
|||
|
694,620 |
119,701 | 32,760,228 | 97,522 |
In light of the foregoing vote and consistent with the prior
recommendation of the Board of Directors, the Company intends to
hold future non-binding advisory votes on executive compensation
on an annual basis until the next required advisory vote on the
frequency of stockholder votes on executive compensation.
| 4. |
The appointment of Ernst Young LLP as our independent registered public accounting firm for the current fiscal year was ratified. |
|
VotesFor |
VotesAgainst |
VotesAbstaining |
BrokerNon-Votes |
|||
|
43,506,300 |
188,343 | 138,122 |
About Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Recent Trading Information
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) closed its last trading session down -0.07 at 1.74 with 276,225 shares trading hands.
